lapatinib has been researched along with tridemorph in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (tridemorph) | Trials (tridemorph) | Recent Studies (post-2010) (tridemorph) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 997 | 7 | 301 |
| Protein | Taxonomy | lapatinib (IC50) | tridemorph (IC50) |
|---|---|---|---|
| Cycloeucalenol cycloisomerase | Zea mays | 0.4 | |
| Sterol-8,7-isomerase | Zea mays | 0.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Flores, LM; Hemler, ME; Krop, IE; Li, Q; Xu, F; Yang, XH; Zhou, P | 1 |
1 other study(ies) available for lapatinib and tridemorph
| Article | Year |
|---|---|
Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antineoplastic Agents; Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Focal Adhesion Protein-Tyrosine Kinases; Humans; Integrin alpha3beta1; Integrin alpha6beta4; Kalinin; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tetraspanin 24; Trastuzumab | 2010 |